EverHint – Momentum Swing — Aggressive Momentum for Apr 15, 2026 – 3 Signals – Healthcare Leads (1)

3 signals. Healthcare leads (1). 1 with insider selling. price range $69-$1007. sectors: Healthcare (1), Technology (1), Communication Services (1). full analyst coverage, earnings data, 66.7% have news.

What This Signal Is (Quick)

Aggressive Momentum is a momentum swing trading strategy focused on Triple threat: high momentum + high volume + high volatility.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

  • Stock showing strong momentum near or at highs
  • Increased volume confirms institutional interest
  • Breaking out or consolidating near resistance
  • Triple threat: high momentum + high volume + high volatility

Ideal For: Aggressive traders seeking maximum momentum with high risk/reward

Key Criteria:

  • Strong RSI momentum (configurable thresholds)

  • Volume surge above average

  • Price momentum confirmation

  • Minimum ADV: $25M+ (varies by variant)

  • Earnings buffer: 7 days pre/post earnings

  • Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High


How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)


📊 Momentum Swing — Aggressive Momentum Signals (3 Total)

Ranked by score:

Rank Ticker Company Sector Last ($) Score Vol Thrust @52w Insider Net Days → Earnings Est EPS Mkt Cap ($B)
1 SYRE Spyre Therapeutics, Inc. Healthcare 68.99 0.300 3.46x 0.0% $-1.5M 21 $-3.74 4.2
2 UI Ubiquiti Inc. Technology 1006.56 0.150 2.00x 0.0% 22 $18.94 60.9
3 GSAT Globalstar, Inc. Communication Services 80.64 0.000 2.03x 0.0% 21 $1.05 10.4

Field Notes

Sector concentration: Healthcare (1), Technology (1), Communication Services (1)

Insider selling: SYRE (Spyre Therapeutics, Inc., $-1.5M)

Data coverage: 33.3% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 66.7% news


Peer Analysis

Understanding how these stocks relate to their industry peers:

GSAT (Globalstar, Inc.): Leads 6 peers: TKC ($6.44, +0.3%), TDS ($44.68, -1.8%), PHI ($20.53, -0.6%), LUMN ($8.59, +10.1%), MSGS ($334.80, -1.4%) | Peer of: MSGS ($334.80, -1.4%), NXST ($196.59, +1.3%), TKC ($6.44, +0.3%)

SYRE (Spyre Therapeutics, Inc.): Leads 10 peers: PHVS ($29.14, +1.6%), IMNM ($23.39, +2.1%), WVE ($7.59, +2.7%), NTLA ($14.94, +1.1%), ZYME ($27.73, +2.8%) | Peer of: ABCL ($3.86, +2.7%), ARDX ($6.30, -0.5%), AZTA ($24.95, +2.8%) and 12 more

UI (Ubiquiti Inc.): Leads 10 peers: NOK ($9.99, -3.5%), MPWR ($1353.00, -0.8%), EA ($203.24, +0.2%), TTWO ($214.15, +4.4%), CLS ($381.94, -0.6%) | Peer of: CLS ($381.94, -0.6%), EA ($203.24, +0.2%), FICO ($1030.81, +2.3%) and 8 more


Recent Headlines

SYRE (Spyre Therapeutics, Inc.)

  • Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade (source)
  • Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock (source)
  • Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026 (source)
  • Spyre Therapeutics Announces Proposed Public Offering of its Common Stock (source)
  • Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript (source)
  • Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug (source)
  • Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients (source)
  • Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 (source)

UI (Ubiquiti Inc.)

  • Diversify Advisory Services LLC Has $1.28 Million Holdings in Ubiquiti Inc. $UI (source)

Market Context

The broader market exhibits a mixed but predominantly bullish tone, with the S&P 500 advancing 0.79% and the Nasdaq surging 1.59%, while the Dow edges lower by 0.15%. This divergence highlights strength in growth-oriented segments, fostering a risk-on environment conducive to aggressive momentum swing strategies. With only three signals generated, the focus narrows to high-conviction opportunities, particularly in the leading Healthcare sector, where rotation appears to favor resilient areas amid selective pressure on industrials.

Declining VIX at 18.06 (-1.63%) signals moderating volatility, which tempers intraday swings and reduces the risk of sharp reversals. For aggressive momentum plays, this creates a favorable setup for riding short-term trends, as lower fear levels allow positions to develop without excessive whipsaws. However, traders should remain vigilant for range-bound action in a calmer backdrop, prioritizing entries aligned with the upward bias in major indices.

Sector rotation toward Healthcare underscores a blend of defensive positioning and opportunistic momentum, amplified by Nasdaq's outperformance. This dynamic supports the strategy's emphasis on swing trades, as capital flows into top sectors amid overall risk appetite, though Dow softness warrants caution on overextended moves.

Sharing Call-to-Action

💡 If you found this useful, a quick like, share, or subscribe keeps EverHint moving forward.


Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/